While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, analysts from William Blair worried that adverse events are not tapering off as expected.
Lilly Takes Victory Lap on Oral Weight Loss Drug as Analysts Spot Safety Crack Read More »
Jacqueline Corrigan-Curay, who stepped into the role as the agency’s top drug regular in January, is departing in July, according to an email sent to agency staff.
Acting CDER Head Becomes Latest in String of FDA Leaders to Leave Agency Read More »
On Friday, the Trump administration finalized a rule that’s expected to cause between 725,000 and 1.8 million people to lose ACA coverage.
CMS slashes ACA sign-up periods, tightens eligibility in final rule Read More »
In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug candidate as a successor to cabozantinib, which is set to lose patent exclusivity in 2030.
The chief product and customer experience officer said Insulet has seen an uptick in users with Type 2 diabetes since receiving an expanded indication, and shared an update on plans for a closed-loop system.
Insulet’s Eric Benjamin shares update on automated insulin delivery system Read More »
Medicaid cuts under consideration in Congress could push hundreds of rural hospitals into further financial distress and impact obstetrics care, according to a report from the Chartis Center for Rural Health.
Medicaid cuts would push struggling rural hospitals ‘over the edge’: report Read More »
Al momento de evaluar seminuevos Monterrey, uno de los factores que más atención recibe por parte de los compradores es el kilometraje. Y aunque este dato puede ofrecer pistas sobre el desgaste del vehículo, no siempre es un indicador definitivo de su estado general. Aquí …
¿Qué tan importante es el kilometraje al comprar un auto usado? Read More »
After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the GLP1-RA class, while reporting mid-stage data for its GLP1- and amylin-targeting drug amycretin that raised dosing questions.
Novo Leans on CagriSema’s Safety as Amycretin Moves Forward to Phase III Read More »
Attorney General Dave Yost set 10 conditions to allow the deal to move forward, including increasing the purchase price by $15 million in cash and an additional $15 million in equity.
Ohio attorney general approves Summa Health sale to General Catalyst Read More »
Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called COMP360’s efficacy “more than good enough” for registrational purposes.
